MedDataX Logo

Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)

NCT ID: NCT00770289

Last Updated: 2012-08-31

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

851 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-05-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD. The evaluation will involve the use of HAM-D 17, and HAM-D 7 questionnaires and the comparison of those questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

12 weeks random

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single group

Cohort

Intervention Type OTHER

Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cohort

Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients
* 18-75 years old
* Patients diagnosed with MDD according to DSM IV without psychotic symptoms
* HAM-D17 \> or = 18 on inclusion
* Patients receiving treatment for the first time or changing treatment based on their doctor's decision

Exclusion Criteria

* Subjects with potentially problematic compliance
* Subjects participating in an interventional trial within the last 3 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Haidari, Athens, Greece

Site Status

Pfizer Investigational Site

Haidari, Athens, Greece

Site Status

Pfizer Investigational Site

Ilissia, Athens, Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0600B-102374&StudyName=Study%20comparing%20remission%20rates%2C%20in%20patients%20with%20%20Major%20Depressive%20Disorder%20%28MDD%29

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2411003

Identifier Type: OTHER

Identifier Source: secondary_id

0600B-102374

Identifier Type: -

Identifier Source: org_study_id